Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib

NCT00486538 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT00486538
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00486538 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 2 Study to Evaluate the Efficacy and Tolerability of ABT-869 in Subjects With Advanced Renal Cell Carcinoma (RCC) Who Have Previously Received Treatment With Sunitinib
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2007
Completion date
June 30, 2012
Enrollment
53 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced renal cell carcinoma